.Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XX05_Lutetium177luVipivotideT.Lutetium177luVipivotideT .Pharmacolibrary.Drugs.V_Various.V10X_OtherTherapeuticRadiopharmaceuticals.V10XX05_Lutetium177luVipivotideT.Lutetium177luVipivotideT| name: | Lutetium177luVipivotideTetraxetan | |
| ATC code: | V10XX05 | |
| route: | intravenous | |
| compartments: | 2 | |
| dosage: | 7400 | mg |
| volume of distribution: | 60 | L |
| clearance: | 5.8 | liter/hour |
| other parameters in model implementation | ||
Lutetium (177Lu) vipivotide tetraxetan (INN; formerly known as lutetium-177 PSMA-617, trade name Pluvicto) is a radioligand therapeutic used for the treatment of prostate-specific membrane antigen (PSMA)-positive metastatic castration-resistant prostate cancer (mCRPC). Administered intravenously, it delivers targeted radiation to PSMA-expressing cancer cells. It is approved for clinical use in certain advanced prostate cancers.
Pharmacokinetic parameters reported in adult male patients with PSMA-positive metastatic castration-resistant prostate cancer following intravenous administration.